Ghana approves Oxford malaria vaccine

0
1986
Ghana approves Oxford malaria vaccine | Baaghi TV

In a breakthrough move, Ghana becomes the first country to approve the Oxford malaria vaccine, touted to be “highly effective”, the R21 vaccine is cleared in West Africa as funding concerns remain. 

Ghana is the first country to approve the malaria vaccine developed at UK’s prestigious Oxford University. The R21/Matrix-M vaccine has been cleared for use by Ghana’s Food and Drugs Authority (FDA) for children between the ages of five and thirty-six months, as this is the group at the highest risk of death from malaria. 

Four killed in firing at Indian military station in Bathinda Punjab, shooters at large

AJK Supreme Court dismisses ex-PM Tanveer Ilyas’ appeal

Court expresses indignation at non-appearance of Petitioner PTI leaders

Imran-Bushra’s first Nikah was not as per Shariah, Mufti Saeed apprises court

The vaccine is the first to meet the World Health Organization (WHO)’s target of seventy-five percent efficacy. Director of the Jenner Institute, Prof. Adrian Hill, said: “This marks a culmination of 30 years of malaria vaccine research at Oxford”. According to Prof. Hill, the vaccine is such that it can be adequately supplied to countries that are most in need of it. 

Ghana approves Oxford malaria vaccine | Baaghi TV

On the other hand, experts have cautioned that it is “no silver bullet” as far as the global fight against malaria is concerned. According to WHO estimates, 619,000 lives were lost in 2021 alone, of which a vast majority were African children from the sub-Saharan region. Especially in Ghana, where the disease is at an endemic level, there are an estimated 3.5 million cases of which there are 12,500 recorded deaths.

Federal govt to pay salaries and pensions before Eid, assures Ishaq Dar

Latif Afridi Murder Case: Decision comes on Bail Application of the Accused

PIA issues statement on Non-payment of salaries

Millie Bobby Brown, Jake Bongiovi announce engagement

Despite approval from Ghana’s FDA, WHO has yet to recommend the widespread use of the breakthrough vaccine, which leaves concerns for necessary international funding. 

According to a The Guardian report, the vaccine is currently in its phase 3 trial and has shown an efficacy of 75% to date. In comparison, the RTS,S vaccine which is normally recommended by WHO since 2021 has more “modest efficacy levels” reported The Guardian.

Meanwhile, the Serum Institute of India, known for manufacturing the R21 vaccine has said that it has the potential to manufacture over 200 million doses per year. Adar Poonawalla, CEO of the Serum Institute said: “Developing a vaccine to greatly impact this huge disease burden has been extraordinarily difficult”.

China’s Position on the Afghan Issue

Three terrorist killed in Bajaur IBO by Army

Pakistan Will Hit Terror Hideouts Inside Afghanistan, Defense Minister Warns Kabul

Coalition parties reject Supreme Court larger bench, terms it as ‘controversial

Ghana approves Oxford malaria vaccine | Baaghi TV

The R21/Matrix-M vaccine has shown efficacy levels of 77%. Photograph: Yasuyoshi Chiba/AFP/Getty Images

Poonawalla added that the institute remains “steadfast” in its commitment to improving production in order to help “support global efforts towards saving lives”.

On the other hand, Javier Guzman who is the director of global health policy at the Center for Global Development said that although the news of the R21 vaccine is “exciting” it does not ensure donors like Gavi, part of the vaccine alliance, would fund it. According to Guzman, such agencies require a bill of approval that the “vaccine is considered safe, effective and quality assured by the WHO pre-qualification programme”. 

Viceroy Research accused of Russian spy links, attacks on UK submarines

Saudi Arabia hosts landmark delegations from Iran and Syria on marathon diplomatic victory

Why did Macron visit China?

Over 10 Thousand new cases reported in India

Stay tuned to Baaghi TV for more. Download our app for the latest news, updates & interesting content!

Leave a reply